City of Hope | Strategic Alliance Partners

Daphne B. Stewart, MD, discusses the progress that has been made with immunotherapy in ovarian cancer, provides insight into the focus on combination therapy with checkpoint inhibitors, and explains the impact of negative trials on the field.

Stephen J. Lee, MD, discusses the trials that have added to existing controversies regarding the optimal management of patients with newly diagnosed advanced ovarian cancer and highlights best practices for deciding between the approaches.

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology and Therapeutics Research, director, Women’s Cancer Programs, and breast cancer oncologist, City of Hope, discusses brain metastases in women with HER2-positive breast cancer.

Ernest S. Han, MD, PhD, FACOG, discusses the role of HIPEC in advanced ovarian cancer at the time of interval debulking, as well as anticipated research examining its use at time of primary debulking.

Joanne Mortimer, MD, discusses key facets of treatment for patients with early and metastatic HER2-positive breast cancer.

Daphne B. Stewart, MD, highlights the pivotal trials evaluating CDK4/6 inhibitors and what unanswered questions remain with this class of agents.

Laura Kruper, MD, MS, discusses outstanding questions within the context of the current management of the axilla.

Sayeh Lavasani, MD, MS, discusses the application of gene assays in the management of patients with hormone receptor-positive breast cancer, as well as ongoing research in this space.

Yuan Yuan, MD, PhD, discusses how treating physicians are optimizing novel agents for patients with metastatic triple-negative breast cancer.

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.

Scott Glaser, MD, assistant clinical professor of radiation oncology, City of Hope, discusses strategies for managing radiation-induced adverse events in patients with early-stage breast cancer.

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of immunotherapy in patients with microsatellite stable (MSS) colon cancer.

City of Hope recently received $7.5 million in grant awards to study a rare type of blood cancer that affects the skin: cutaneous T cell lymphoma.

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the use of regional therapy in the treatment of patients with colorectal cancer (CRC).

The recent technological advances in medicine and related fields have encouraged a belief among many that there is little technology will not be able to accomplish in improving cancer-related clinical outcomes, but it must be acknowledged that clinical medicine and cancer biology are extremely complex arenas.

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.

Vincent Chung, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, director of the Phase I Program, City of Hope, discusses the COMPASS trial in pancreatic cancer.

An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute.

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the benefit of cytoreductive surgery in the treatment of patients with metastatic colorectal cancer (mCRC).

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses sequencing in metastatic castration-resistant prostate cancer (mCRPC).

Byrne Lee, MD, chief, Upper GI and Mixed Tumor Surgery Service, associate professor of surgical oncology, City of Hope, discusses the differences between HIPEC and PIPAC in the treatment of patients with metastatic colorectal cancer.

Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.

Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.

Daneng Li, MD, an assistant clinical professor in the Department of Medical Oncology and Therapeutics Research, and a medical oncologist at City of Hope, discusses an ongoing study of preoperative immunotherapy in patients with hepatocellular carcinoma (HCC).

Marwan Fakih, MD, professor, Department of Medical Oncology and Therapeutics Research, associate director for Clinical Investigations, Comprehensive Cancer Center, medical director, Judy and Bernard Briskin Center for Clinical Research, co-director, Gastrointestinal Cancer Program, and section head, Gastrointestinal Medical Oncology, City of Hope, discusses the clinical utility of the Immunoscore in patients with colorectal cancer.

Vincent Chung, MD, discusses the therapeutic landscape of early-stage and advanced pancreatic cancer.

Daneng Li, MD, shed light on some of the currently available regimens and ongoing research efforts being conducted in hepatocellular carcinoma and neuroendocrine tumors.

Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the status of immunotherapy in prostate cancer.

Joseph Chao, MD, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses practice-changing data in metastatic gastroesophageal (GEJ) cancer.